{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,10]],"date-time":"2026-07-10T06:16:12Z","timestamp":1783664172784,"version":"3.55.0"},"reference-count":56,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,7,10]],"date-time":"2026-07-10T00:00:00Z","timestamp":1783641600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:sec>\n                    <jats:title>Introduction<\/jats:title>\n                    <jats:p>Peripheral T-cell lymphoma (PTCL) is a heterogeneous and highly aggressive subtype of non-Hodgkin lymphoma. Approximately 30% of patients develop relapsed or refractory PTCL (R\/R PTCL) due to disease recurrence or failure to achieve complete remission after first-line therapy. Despite therapeutic advances, the molecular and cellular mechanisms underlying treatment resistance in R\/R PTCL remain unclear.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Single-cell RNA sequencing and single-cell T-cell receptor sequencing were performed on seven tumor samples from six patients with R\/R PTCL. These approaches were used to systematically characterize the transcriptional profiles of malignant T-cell clones and reactive T lymphocytes, define the transcriptomic landscape of R\/R PTCL, and identify potential epigenetic biomarkers associated with drug response.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>We observed significant upregulation of genes associated with cell proliferation, oncogenic signaling, and immune modulation in R\/R PTCL. Within the tumor microenvironment, specific protumorigenic ligand\u2013receptor interactions were identified, including CXCL13\u2013CXCR5, CCL5\u2013CCR5, and CD74\u2013MIF interactions, which may facilitate immune evasion by malignant T cells. Longitudinal analysis of a patient who progressed following dual epigenetic therapy revealed marked downregulation of immune response-related genes, including HLA-DRA\/DPA1\/DRB5, CD74, C1QC, and LYZ, as well as functional reprogramming of tumor-associated macrophages. Enhanced LGALS9\u2013HAVCR2 and CSF1\u2013CSF1R interactions were also observed following combination treatment with chidamide and azacitidine.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Discussion<\/jats:title>\n                    <jats:p>This study delineates the transcriptional heterogeneity of malignant T-cell clones in R\/R PTCL and suggests that this heterogeneity may contribute to resistance to epigenetic therapies. These findings provide novel insights into the molecular mechanisms underlying treatment resistance and highlight potential avenues for therapeutic intervention in R\/R PTCL.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fimmu.2026.1790664","type":"journal-article","created":{"date-parts":[[2026,7,10]],"date-time":"2026-07-10T05:38:18Z","timestamp":1783661898000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Single-cell sequencing uncovers clonal dynamics profiles and therapeutic resistance biomarkers in relapsed and refractory peripheral T-cell lymphoma"],"prefix":"10.3389","volume":"17","author":[{"given":"Ning","family":"Zhang","sequence":"first","affiliation":[{"name":"State Key Laboratory of Druggability Evaluation and Systematic Translational Medicine\/Department of Lymphoma, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Tianjin\u2019s Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy, the Sino-US Center for Lymphoma and Leukemia Research","place":["Tianjin, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jingwei","family":"Yu","sequence":"additional","affiliation":[{"name":"State Key Laboratory of Druggability Evaluation and Systematic Translational Medicine\/Department of Lymphoma, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Tianjin\u2019s Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy, the Sino-US Center for Lymphoma and Leukemia Research","place":["Tianjin, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hengqi","family":"Liu","sequence":"additional","affiliation":[{"name":"State Key Laboratory of Druggability Evaluation and Systematic Translational Medicine\/Department of Lymphoma, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Tianjin\u2019s Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy, the Sino-US Center for Lymphoma and Leukemia Research","place":["Tianjin, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zechao","family":"Hu","sequence":"additional","affiliation":[{"name":"State Key Laboratory of Druggability Evaluation and Systematic Translational Medicine\/Department of Lymphoma, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Tianjin\u2019s Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy, the Sino-US Center for Lymphoma and Leukemia Research","place":["Tianjin, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shen","family":"Meng","sequence":"additional","affiliation":[{"name":"State Key Laboratory of Druggability Evaluation and Systematic Translational Medicine\/Department of Lymphoma, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Tianjin\u2019s Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy, the Sino-US Center for Lymphoma and Leukemia Research","place":["Tianjin, China"]},{"name":"Department of Radiation Oncology, Shandong Cancer Hospital and Institute, Shandong First Medical University, Shandong Academy of Medical Sciences","place":["Jinan, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cong","family":"Sun","sequence":"additional","affiliation":[{"name":"State Key Laboratory of Druggability Evaluation and Systematic Translational Medicine\/Department of Lymphoma, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Tianjin\u2019s Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy, the Sino-US Center for Lymphoma and Leukemia Research","place":["Tianjin, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yaxiao","family":"Lu","sequence":"additional","affiliation":[{"name":"State Key Laboratory of Druggability Evaluation and Systematic Translational Medicine\/Department of Lymphoma, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Tianjin\u2019s Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy, the Sino-US Center for Lymphoma and Leukemia Research","place":["Tianjin, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xia","family":"Liu","sequence":"additional","affiliation":[{"name":"State Key Laboratory of Druggability Evaluation and Systematic Translational Medicine\/Department of Lymphoma, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Tianjin\u2019s Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy, the Sino-US Center for Lymphoma and Leukemia Research","place":["Tianjin, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zheng","family":"Song","sequence":"additional","affiliation":[{"name":"State Key Laboratory of Druggability Evaluation and Systematic Translational Medicine\/Department of Lymphoma, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Tianjin\u2019s Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy, the Sino-US Center for Lymphoma and Leukemia Research","place":["Tianjin, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lanfang","family":"Li","sequence":"additional","affiliation":[{"name":"State Key Laboratory of Druggability Evaluation and Systematic Translational Medicine\/Department of Lymphoma, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Tianjin\u2019s Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy, the Sino-US Center for Lymphoma and Leukemia Research","place":["Tianjin, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lihua","family":"Qiu","sequence":"additional","affiliation":[{"name":"State Key Laboratory of Druggability Evaluation and Systematic Translational Medicine\/Department of Lymphoma, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Tianjin\u2019s Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy, the Sino-US Center for Lymphoma and Leukemia Research","place":["Tianjin, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhengzi","family":"Qian","sequence":"additional","affiliation":[{"name":"State Key Laboratory of Druggability Evaluation and Systematic Translational Medicine\/Department of Lymphoma, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Tianjin\u2019s Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy, the Sino-US Center for Lymphoma and Leukemia Research","place":["Tianjin, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bin","family":"Meng","sequence":"additional","affiliation":[{"name":"Department of Pathology, Tianjin Medical University Cancer Institute and Hospital","place":["Tianjin, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenchen","family":"Gong","sequence":"additional","affiliation":[{"name":"Department of Pathology, Tianjin Medical University Cancer Institute and Hospital","place":["Tianjin, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shiyong","family":"Zhou","sequence":"additional","affiliation":[{"name":"State Key Laboratory of Druggability Evaluation and Systematic Translational Medicine\/Department of Lymphoma, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Tianjin\u2019s Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy, the Sino-US Center for Lymphoma and Leukemia Research","place":["Tianjin, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xianhuo","family":"Wang","sequence":"additional","affiliation":[{"name":"State Key Laboratory of Druggability Evaluation and Systematic Translational Medicine\/Department of Lymphoma, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Tianjin\u2019s Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy, the Sino-US Center for Lymphoma and Leukemia Research","place":["Tianjin, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huilai","family":"Zhang","sequence":"additional","affiliation":[{"name":"State Key Laboratory of Druggability Evaluation and Systematic Translational Medicine\/Department of Lymphoma, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Tianjin\u2019s Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy, the Sino-US Center for Lymphoma and Leukemia Research","place":["Tianjin, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,7,10]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1007\/s11912-022-01310-3","article-title":"Management of peripheral t-cell lymphomas and the role of transplant","volume":"24","author":"Foley","year":"2022","journal-title":"Curr Oncol Rep"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-022-01620-2","article-title":"The 5th edition of the world health organization classification of haematolymphoid tumours: Lymphoid neoplasms","volume":"36","author":"Alaggio","year":"2022","journal-title":"Leukemia"},{"key":"B3","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1186\/s13045-024-01560-7","article-title":"Novel clinical risk stratification and treatment strategies in relapsed\/refractory peripheral t-cell lymphoma","volume":"17","author":"Chang","year":"2024","journal-title":"J Hematol Oncol"},{"key":"B4","doi-asserted-by":"publisher","first-page":"285","DOI":"10.6004\/jnccn.2022.0015","article-title":"T-cell lymphomas, version 2.2022, nccn clinical practice guidelines in oncology","volume":"20","author":"Horwitz","year":"2022","journal-title":"J Natl Compr Canc Netw"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1002\/hon.2924","article-title":"Comparison of first-line treatments of peripheral t-cell lymphoma according to regimen: A systematic review and meta-analysis","volume":"39","author":"Kim","year":"2021","journal-title":"Hematol Oncol"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1016\/j.lanwpc.2021.100126","article-title":"Comprehensive analysis of peripheral t-cell and natural killer\/t-cell lymphoma in asian patients: A multinational, multicenter, prospective registry study in asia","volume":"10","author":"Yoon","year":"2021","journal-title":"Lancet Reg Health West Pac"},{"key":"B7","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1186\/s40164-020-00188-w","article-title":"Molecular insights into pathogenesis and targeted therapy of peripheral t cell lymphoma","volume":"9","author":"Xie","year":"2020","journal-title":"Exp Hematol Oncol"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1016\/s1470-2045(24)00503-5","article-title":"Valemetostat for patients with relapsed or refractory peripheral t-cell lymphoma (valentine-ptcl01): A multicentre, open-label, single-arm, phase 2 study","volume":"25","author":"Zinzani","year":"2024","journal-title":"Lancet Oncol"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.13566","article-title":"The combination of hypomethylating agents and histone deacetylase inhibitors produce marked synergy in preclinical models of t-cell lymphoma","volume":"171","author":"Marchi","year":"2015","journal-title":"Br J Haematol"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2019001285","article-title":"Oral 5-azacytidine and romidepsin exhibit marked activity in patients with ptcl: A multicenter phase 1 study","volume":"134","author":"O'Connor","year":"2019","journal-title":"Blood"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2020009004","article-title":"Combined oral 5-azacytidine and romidepsin are highly effective in patients with ptcl: A multicenter phase 2 study","volume":"137","author":"Falchi","year":"2021","journal-title":"Blood"},{"key":"B12","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1038\/nbt.3192","article-title":"Spatial reconstruction of single-cell gene expression data","volume":"33","author":"Satija","year":"2015","journal-title":"Nat Biotechnol"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1038\/s41592-019-0619-0","article-title":"Fast, sensitive and accurate integration of single-cell data with harmony","volume":"16","author":"Korsunsky","year":"2019","journal-title":"Nat Methods"},{"key":"B14","doi-asserted-by":"publisher","first-page":"1888","DOI":"10.1016\/j.cell.2019.05.031","article-title":"Comprehensive integration of single-cell data","volume":"177","author":"Stuart","year":"2019","journal-title":"Cell"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1038\/nbt.4096","article-title":"Integrating single-cell transcriptomic data across different conditions, technologies, and species","volume":"36","author":"Butler","year":"2018","journal-title":"Nat Biotechnol"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1038\/nmeth.4612","article-title":"Bias, robustness and scalability in single-cell differential expression analysis","volume":"15","author":"Soneson","year":"2018","journal-title":"Nat Methods"},{"key":"B17","doi-asserted-by":"publisher","first-page":"3573","DOI":"10.1016\/j.cell.2021.04.048","article-title":"Integrated analysis of multimodal single-cell data","volume":"184","author":"Hao","year":"2021","journal-title":"Cell"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1089\/omi.2011.0118","article-title":"Clusterprofiler: An r package for comparing biological themes among gene clusters","volume":"16","author":"Yu","year":"2012","journal-title":"Omics"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2105-14-7","article-title":"Gsva: Gene set variation analysis for microarray and rna-seq data","volume":"14","author":"H\u00e4nzelmann","year":"2013","journal-title":"BMC Bioinf"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1038\/nmeth.4150","article-title":"Single-cell mrna quantification and differential analysis with census","volume":"14","author":"Qiu","year":"2017","journal-title":"Nat Methods"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1038\/s41596-020-0292-x","article-title":"Cellphonedb: Inferring cell-cell communication from combined expression of multi-subunit ligand-receptor complexes","volume":"15","author":"Efremova","year":"2020","journal-title":"Nat Protoc"},{"key":"B22","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1186\/s13045-017-0439-6","article-title":"Chidamide in relapsed or refractory peripheral t cell lymphoma: A multicenter real-world study in China","volume":"10","author":"Shi","year":"2017","journal-title":"J Hematol Oncol"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2022018254","article-title":"Multicenter phase 2 study of oral azacitidine (cc-486) plus chop as initial treatment for ptcl","volume":"141","author":"Ruan","year":"2023","journal-title":"Blood"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccell.2025.04.006","article-title":"Regulating the fate of tumor-associated macrophages","volume":"43","author":"Timosenko","year":"2025","journal-title":"Cancer Cell"},{"key":"B25","doi-asserted-by":"publisher","first-page":"e178540","DOI":"10.1172\/jci178540","article-title":"Epigenetic regulation of tumor immunity","volume":"134","author":"Pang","year":"2024","journal-title":"J Clin Invest"},{"key":"B26","doi-asserted-by":"publisher","first-page":"589","DOI":"10.3390\/cancers15030589","article-title":"Therapeutic advances in relapsed and refractory peripheral t-cell lymphoma","volume":"15","author":"Stuver","year":"2023","journal-title":"Cancers (Basel)"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1186\/s12943-023-01904-w","article-title":"Therapeutic challenges in peripheral t-cell lymphoma","volume":"23","author":"Luan","year":"2024","journal-title":"Mol Cancer"},{"key":"B28","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1186\/s13073-016-0335-7","article-title":"Single-cell tcrseq: Paired recovery of entire t-cell alpha and beta chain transcripts in t-cell receptors from single-cell rnaseq","volume":"8","author":"Redmond","year":"2016","journal-title":"Genome Med"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1038\/nbt.2938","article-title":"Linking t-cell receptor sequence to functional phenotype at the single-cell level","volume":"32","author":"Han","year":"2014","journal-title":"Nat Biotechnol"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-021-03626-9","article-title":"Tim-3 restrains anti-tumour immunity by regulating inflammasome activation","volume":"595","author":"Dixon","year":"2021","journal-title":"Nature"},{"key":"B31","doi-asserted-by":"publisher","first-page":"649","DOI":"10.1016\/j.ccell.2021.02.015","article-title":"Tumor and immune reprogramming during immunotherapy in advanced renal cell carcinoma","volume":"39","author":"Bi","year":"2021","journal-title":"Cancer Cell"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.3389\/fcell.2021.822315","article-title":"Single-cell rna-seq reveals the promoting role of ferroptosis tendency during lung adenocarcinoma emt progression","volume":"9","author":"Yao","year":"2021","journal-title":"Front Cell Dev Biol"},{"key":"B33","doi-asserted-by":"publisher","first-page":"3684","DOI":"10.1038\/s41467-021-24010-1","article-title":"Single-cell rna sequencing shows the immunosuppressive landscape and tumor heterogeneity of hbv-associated hepatocellular carcinoma","volume":"12","author":"Ho","year":"2021","journal-title":"Nat Commun"},{"key":"B34","doi-asserted-by":"publisher","first-page":"e2105822118","DOI":"10.1073\/pnas.2105822118","article-title":"Single-cell profiling reveals the importance of cxcl13\/cxcr5 axis biology in lymphocyte-rich classic hodgkin lymphoma","volume":"118","author":"Aoki","year":"2021","journal-title":"Proc Natl Acad Sci USA"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2018.196725","article-title":"Ccr5 antagonism by maraviroc inhibits hodgkin lymphoma microenvironment interactions and xenograft growth","volume":"104","author":"Casagrande","year":"2019","journal-title":"Haematologica"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1612195114","article-title":"Cd74 is a novel transcription regulator","volume":"114","author":"Gil-Yarom","year":"2017","journal-title":"Proc Natl Acad Sci USA"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1038\/jid.2015.204","article-title":"Cell surface cd74-mif interactions drive melanoma survival in response to interferon-\u03b3","volume":"135","author":"Tanese","year":"2015","journal-title":"J Invest Dermatol"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1080\/2162402x.2020.1846915","article-title":"Mif inhibition as a strategy for overcoming resistance to immune checkpoint blockade therapy in melanoma","volume":"9","author":"de Azevedo","year":"2020","journal-title":"Oncoimmunology"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.1102152","article-title":"Role of macrophage migration inhibitory factor in the regulatory t cell response of tumor-bearing mice","volume":"189","author":"Choi","year":"2012","journal-title":"J Immunol"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1038\/s41422-022-00627-9","article-title":"Defined tumor antigen-specific t cells potentiate personalized tcr-t cell therapy and prediction of immunotherapy response","volume":"32","author":"He","year":"2022","journal-title":"Cell Res"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.1038\/s43018-022-00433-7","article-title":"Single-cell meta-analyses reveal responses of tumor-reactive cxcl13(+) t cells to immune-checkpoint blockade","volume":"3","author":"Liu","year":"2022","journal-title":"Nat Cancer"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.1200\/jco.2017.77.3994","article-title":"Major histocompatibility complex class ii and programmed death ligand 1 expression predict outcome after programmed death 1 blockade in classic hodgkin lymphoma","volume":"36","author":"Roemer","year":"2018","journal-title":"J Clin Oncol"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.1158\/2326-6066.Cir-15-0243","article-title":"Expression of the mhc class ii pathway in triple-negative breast cancer tumor cells is associated with a good prognosis and infiltrating lymphocytes","volume":"4","author":"Forero","year":"2016","journal-title":"Cancer Immunol Res"},{"key":"B44","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1186\/s13148-023-01436-6","article-title":"Aberrant jak-stat signaling-mediated chromatin remodeling impairs the sensitivity of nk\/t-cell lymphoma to chidamide","volume":"15","author":"Chen","year":"2023","journal-title":"Clin Epigenet"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2022.977266","article-title":"Epigenetic regulation of cutaneous t-cell lymphoma is mediated by dysregulated lncrna malat1 through modulation of tumor microenvironment","volume":"12","author":"Guo","year":"2022","journal-title":"Front Oncol"},{"key":"B46","doi-asserted-by":"publisher","first-page":"116335","DOI":"10.1016\/j.lfs.2019.03.040","article-title":"Lncrna malat1 promotes tumorigenesis and immune escape of diffuse large b cell lymphoma by sponging mir-195","volume":"231","author":"Wang","year":"2019","journal-title":"Life Sci"},{"key":"B47","doi-asserted-by":"publisher","first-page":"346","DOI":"10.1186\/s12967-016-1100-9","article-title":"Lncrna malat1 promotes development of mantle cell lymphoma by associating with ezh2","volume":"14","author":"Wang","year":"2016","journal-title":"J Transl Med"},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2407-14-809","article-title":"Malat1 long non-coding rna is overexpressed in multiple myeloma and may serve as a marker to predict disease progression","volume":"14","author":"Cho","year":"2014","journal-title":"BMC Cancer"},{"key":"B49","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopha.2019.108720","article-title":"Malat1 knockdown inhibits proliferation and enhances cytarabine chemosensitivity by upregulating mir-96 in acute myeloid leukemia cells","volume":"112","author":"Hu","year":"2019","journal-title":"BioMed Pharmacother"},{"key":"B50","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1186\/s12943-021-01464-x","article-title":"Epigenetic modulation of antitumor immunity for improved cancer immunotherapy","volume":"20","author":"Dai","year":"2021","journal-title":"Mol Cancer"},{"key":"B51","doi-asserted-by":"publisher","DOI":"10.1016\/j.it.2020.12.001","article-title":"Monocyte regulation in homeostasis and Malignancy","volume":"42","author":"Robinson","year":"2021","journal-title":"Trends Immunol"},{"key":"B52","doi-asserted-by":"publisher","first-page":"7271","DOI":"10.1038\/s41467-025-61822-x","article-title":"Integrative multi-omics reveals a regulatory and exhausted t-cell landscape in cll and identifies galectin-9 as an immunotherapy target","volume":"16","author":"Lla\u00f3-Cid","year":"2025","journal-title":"Nat Commun"},{"key":"B53","doi-asserted-by":"publisher","first-page":"4388","DOI":"10.1038\/s41467-024-48700-8","article-title":"Single-cell and spatial transcriptomics analysis of non-small cell lung cancer","volume":"15","author":"De Zuani","year":"2024","journal-title":"Nat Commun"},{"key":"B54","doi-asserted-by":"publisher","DOI":"10.1097\/js9.0000000000003306","article-title":"Single-cell rna sequencing reveals immune regulatory mechanisms and molecular therapeutic strategies in the microenvironment of multiple myeloma","volume":"112","author":"Su","year":"2025","journal-title":"Int J Surg"},{"key":"B55","doi-asserted-by":"publisher","DOI":"10.1002\/advs.202500950","article-title":"The cxcl10-cxcr3 axis induces tumor-associated neutrophils to interfere with ctls-mediated antitumor activity in ebv-associated epithelial cancers","volume":"12","author":"Ouyang","year":"2025","journal-title":"Adv Sci (Weinh)"},{"key":"B56","doi-asserted-by":"publisher","DOI":"10.1016\/j.xcrm.2026.102584","article-title":"Efficacy and safety of autologous cd5-ko anti-cd5 car-t cells in relapsed\/refractory cd5(+) hematological Malignancies","volume":"7","author":"Cheng","year":"2026","journal-title":"Cell Rep Med"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1790664\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,10]],"date-time":"2026-07-10T05:38:20Z","timestamp":1783661900000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1790664\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,10]]},"references-count":56,"alternative-id":["10.3389\/fimmu.2026.1790664"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2026.1790664","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,10]]},"article-number":"1790664"}}